Robert Vries, Ph.D

Chief Executive Officer

Robert received his PhD in Biochemistry from the Leiden University Medical Center on the study of Oncogenic cell transformation. He subsequently moved to Stanford University (USA) to do his Post Doc studying neural stem cells. Upon his return to the Netherlands he continued the study of stem cells in the group of Prof. Hans Clevers at the Hubrecht Institute in The Netherlands.

 

In the group of Hans Clevers he was part of the team that developed the breakthrough technology that allowed the expansion of adult stem cells. The so called Organoid Technology became the basis of the non-profit company ‘Hubrecht Organoid Technology'(HUB) of which he is currently the CEO.

July 17, 2019 Epistem license Hubrecht Organoid Technology ... Epistem license Hubrecht Organoid Technology to expand preclinical toxicology service portfolio Manchester, 16th July, 2... read more
July 09, 2019 ‘Het gaat alleen sneller als er geld bij ko... Hubrecht Organoid Technology, kortweg HUB, is als start-up ontstaan op de Uithof, de universiteitscampus in Utrecht. Het... read more
July 09, 2019 Medicijnen betaalbaar houden De kosten van medicijnen zijn de afgelopen 30 jaar flink gestegen. En zullen de komende jaren verder stijgen. CZ gaat ve... read more